October 06, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Ursapharm and Novaliq enter exclusive partnership, launch EvoTears
Novaliq and Ursapharm have entered an exclusive European partnership agreement and together have launched EvoTears, an over-the-counter treatment for evaporative dry eye disease.
Under the agreement, Ursapharm obtains the exclusive license to commercialize Novaliq’s EvoTears, a multi-dose, non-aqueous, non-preserved lubricant eye drop, according to a press release from Novaliq.
The product received CE mark in July 2013.
“The out-licensing of EvoTears in Europe represents the logical next step for us to broaden the visibility of our platform and facilitates our development pipeline of pharmaceutical products with focus on severe eye diseases,” Bernard Günther, co-founder, managing director and CEO of Novaliq, said in the release.